| Q36180179 | A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA. |
| Q36092834 | Apoptosis in SIV infection. |
| Q36092837 | Apoptosis of HIV-specific CD8+ T cells: an HIV evasion strategy. |
| Q24801374 | Apoptosis of uninfected cells induced by HIV envelope glycoproteins |
| Q42626503 | CD4 T Cells Treated with gp120 Acquire a CD45R0+/CD45RA+ Phenotype. |
| Q33394574 | CD8+ T-cell interleukin-7 receptor alpha expression as a potential indicator of disease status in HIV-infected children |
| Q44126949 | CD95 (APO-1/Fas) expression on naive CD4(+) T cells increases with disease progression in HIV-infected children and adolescents: effect of highly active antiretroviral therapy (HAART). |
| Q47965903 | Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapy |
| Q52005732 | Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children. |
| Q35958745 | Constitutive activation and accelerated maturation of peripheral blood T cells in healthy adults in Burkina Faso compared to Germany: the case of malaria? |
| Q52027267 | Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group. |
| Q34743386 | Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3 |
| Q34569082 | Efficacy of highly active antiretroviral therapy in HIV-1 infected children |
| Q90634658 | Enhanced IFN-γ, but not IL-2, response to Mycobacterium tuberculosis antigens in HIV/latent TB co-infected patients on long-term HAART |
| Q39605011 | Exogenous interleukin-2 administration corrects the cell cycle perturbation of lymphocytes from human immunodeficiency virus-infected individuals |
| Q44577471 | HIV protease inhibitors as new treatment options for Kaposi's sarcoma |
| Q35557244 | HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites |
| Q51998478 | HIV-infected children with moderate/severe immune-suppression: changes in the immune system after highly active antiretroviral therapy. |
| Q63236582 | Highly active antiretroviral therapy restores in vitro mitogen and antigen-specific T-lymphocyte responses in HIV-1 perinatally infected children despite virological failure |
| Q34575987 | Immunologic basis for revaccination of HIV-infected children receiving HAART. |
| Q35110073 | Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients |
| Q30882611 | Induction of apoptosis by HIV-1-infected monocytic cells |
| Q33839196 | Infection of the CD45RA+ (naive) subset of peripheral CD8+ lymphocytes by human immunodeficiency virus type 1 in vivo |
| Q35120763 | Mitochondria in HIV-1-induced apoptosis. |
| Q52017637 | Naïve and memory CD4+ T cells and T cell activation markers in HIV-1 infected children on HAART. |
| Q48987735 | Reconstitution of thymic function in HIV-1 patients treated with highly active antiretroviral therapy |
| Q44272943 | Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. |
| Q35895763 | Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment |
| Q36619846 | Supranormal thymic output up to 2 decades after HIV-1 infection |
| Q45710559 | T cell survival/proliferation reconstitution by trifluoperazine in human immunodeficiency virus-1 infection |
| Q74451690 | T-cell re-population in HIV-infected children on highly active anti-retroviral therapy (HAART) |
| Q56912967 | The effect of interrupted anti-retroviral treatment on the reconstitution of memory and naive T cells during tuberculosis treatment in HIV patients with active pulmonary tuberculosis |
| Q34133579 | Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities |
| Q52012623 | [Immunologic recovery after 2-years on HAART in vertically HIV-infected children]. |